Skip to main content
close menu
close menu

Search UK HealthCare

Molecular Tumor Board

The Markey Cancer Center Molecular Tumor Board (MTB) is a statewide service available to physicians at UK HealthCare and regional affiliates.

The MTB provides a forum for expert clinicians, pathologists and scientists to discuss and analyze tumor genotypes and molecular abnormalities in order to recommend patient specific targeted therapies. 

The MTB is intended to supplement oncology tumor boards and includes a broad range of expert panel members.

Clinicians can order a genomic report and submit a case study to be presented for review by the MTB during their twice monthly meetings. For an overview of the MTB, download the referral flyer below.

Download our referral flyer (PDF, 295 KB)

  • Meetings

    The Molecular Tumor Board (MTB) meets:

    • 12 p.m.
    • Every first and third Tuesday
    • Room CC 457, Ben F. Roach Building

    Off-site participants can call in via UK Telehealth. Email the MTB manager to be added to the call in list.

    Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.

    To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.

    MTB Meeting Schedule

    Case Submission Date   Meeting Date 15 Minute Update Topic  Speaker
    01/09/18 01/16/18    
    01/30/18 02/06/18    
    02/13/18 02/20/18    
    02/27/18 03/06/18    
    04/10/18 04/17/18    
    04/24/18 05/21/18    
    05/08/18 05/15/18    
    05/29/18 06/05/18    
    06/12/18 06/19/18    
    06/26/18 07/03/18    
    07/10/18 07/17/18    
    07/31/18 08/07/18    
    08/14/18 08/21/18    
    08/28/18 09/04/18    
    09/11/18 09/18/18    
    09/25/18 10/02/18    
    10/09/18 10/16/18    
    10/30/18 11/06/18    
    11/13/18 11/20/18    
    11/27/18 12/04/18    
    12/11/18 12/18/18    

    Continuing Medical Education (CME)

    If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at  

    Policy on Disclosure

    It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

  • Journal Club

    The MTB Journal Club meets to evaluate current research regarding oncology-based precision medicine at 1 p.m. every first Tuesday in Room CC 457, Ben F. Roach Building.

    • 1 p.m.
    • Every first Tuesday
    • Room CC 457, Ben F. Roach Building

    To find presentations from our Journal Club meetings, visit the MTB's References section.

    03/06/18 Danielle Corbett, PhamD Outsmarting our Genes: Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
    05/15/18 Laura Cannon, PharmD Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
  • Case Submission

    Cases must be submitted at least seven days prior to the meeting date.

    Genomics reports from UK HealthCare or external sources (Foundation, MATCH, etc.) can be submitted.

    A patient's genomic report is required for case submission. Please see how to order a genomic report through UK HealthCare under Order a Genomic Report below. 

    If you already have a genomic report, fill out the case submission form online, or download the form here.

    The patient’s genomic report can be sent to MTB by email.

    When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

    Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed and/or mailed or uploaded into the electronic health record per the preference of the submitting physician. Specify method of results reporting on the case submission form.

    Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

  • Research

    The Molecular Tumor Board currently has two prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

    • Part 1:  A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
    • Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.

    Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.

  • Contact Us

    Directors Site Leaders 

    Jill Kolesar, PharmD

    Professor, College of Pharmacy

    Department of Pharmacy Practice and Science

    Chandler Park, MD, FACP

    Research Medical Director at Hardin Memorial Hospital, Central Kentucky Region

    UK Markey Cancer Center Research Network

    Rachel Ware Miller, MD

    Associate Professor, Division of Gynecologic Oncology

    Department of Obstetrics and Gynecology

    Executive Committee Administrative Office

    Susanne M. Arnold, MD

    Associate Director for Clinical Translation

    Markey Cancer Center

    Marissa Schuh,

    Molecular Tumor Board Manager


    Eric B Durbin, DrPH, MS

    Assistant Professor, College of Medicine

    Division of Biomedical Informatics 


    Lars Wagner, MD

    Professor of Pediatrics, College of Medicine

    Chief, Pediatric Hematology and Oncology


    Kurt Hodges, MD, MBA

    Clinical Faculty

    Department of Pathology, Division of Pathology and Laboratory Medicine


    Ranjana Arora, MD, MPH

    Clinical Faculty

    Department of Pathology, Division of Pathology and Laboratory Medicine


    Cory Vela, PharmD

    Clinical Pharmacy Specialist, Precision Medicine